Copyright © Inderes 2011 - present. All rights reserved.

Faron Pharmaceuticals

2.07

 

EUR

 

+1.72 %

Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

5,011 following
Compare
+1.72%
+16.03%
-20.08%
+81.58%
-45.09%
-43.6%
-37.46%
-33.23%
-40.52%

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
216.57M EUR
Turnover
251.49K EUR
P/E (adj.) (24e)
-7.28
EV/EBIT (adj.) (24e)
-8.45
P/B (24e)
-21.19
EV/S (24e)
55,184.05
Dividend yield-% (24e)
-
Coverage
Recommendation
Accumulate
Target price
2.80 EUR
Updated
2024-12-11
Disclaimer
Latest research

Latest analysis report

Released: 2024-12-11

Latest extensive report

Released: 2022-08-23

Financial calendar
27/2
2025

Annual report '24

21/3
2025

General meeting '24

27/8
2025

Interim report Q2'25

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Research by
Antti Siltanen

Faron: Towards final read-out in March

Faron reported more detailed interim results of the BEXMAB study at the annual meeting of the American Society of Hematology (ASH). The company is on track for the important final read-out in March, as tolerability and overall response rate have remained at good levels.

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Cheers, We’ve recently released an Initiation of Coverage Report on Faron Pharmaceuticals. Faron is a clinical stage drug development company focused on immunology. The lead candidate bexmarilimab is an immuno oncology drug developed for various solid tumors and blood cancers. The...
9/13/2022, 12:16 PM
by Antti Siltanen
4
Part 2 of the article series! Probabilities of success in drug development The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development. Drug development companies typically examine...
9/26/2024, 1:37 PM
by Jesper Hagman
2
A little news from Faron: On Wednesday, Faron Pharmaceuticals published new positive results from the BEXMAB study to examine the efficacy of the company’s precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. Faron also...
7/23/2023, 6:02 PM
by börsen84
2
Hello Antti! Thank you very much for your response and also for the excellent analyses! Without you, interpreting a company like this would be very difficult for me alone. The industry is so challenging for an ordinary investor like myself. You’re doing a great job, and I appreciate...
5/20/2023, 4:31 PM
by börsen84
2
Hi Börsen, Although a bit old, the video and our Initiation of Coverage report are mostly still relevant. The main developments since recording the vid have been the faster than expected development of the phase I/II BEXMAB trial investigating bexmarilimab for treatment of blood ...
5/20/2023, 2:35 PM
by Antti Siltanen
2
Faron received an Innovation Passport in the UK for the treatment of relapsed/refractory myelodysplastic syndrome (r/r MDS) and will initiate the BEXMAB trial, accelerating drug development and patient access to treatments. Inderes Progress for Faron in the UK - Inderes Faron announced...
12/4/2024, 10:09 PM
by börsen84
1
New series of articles! We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply...
9/10/2024, 6:49 AM
by Jesper Hagman
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.